Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Oculis Holding AG Warrants (OCSAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/31/2025: OCSAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 75.18% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 03/31/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 8698 | Beta - | 52 Weeks Range 1.75 - 11.50 | Updated Date 02/26/2025 |
52 Weeks Range 1.75 - 11.50 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Oculis Holding AG Warrants
Company Overview
History and Background
Oculis Holding AG is a biopharmaceutical company focused on developing ophthalmic treatments. The warrants are derivative instruments tied to Oculis Holding AG common stock. Details on founding year and milestones specific to the warrants are limited, as they are associated with the SPAC merger.
Core Business Areas
- Ophthalmic Drug Development: Focuses on developing and commercializing novel treatments for eye diseases.
Leadership and Structure
Specific leadership of the warrant structure typically mirrors that of the underlying company. Oculis Holding AG has a board of directors and executive management team that guide the company's overall strategy.
Top Products and Market Share
Key Offerings
- OCU400: A novel gene therapy product candidate targeting multiple genetic mutations in inherited retinal diseases (IRDs). Market share is currently zero, as it is in clinical trials. Competitors include companies developing gene therapies for specific IRD mutations, such as AGTC and MeiraGTx.
- OCU200: A therapeutic antibody targeting TNFu03b1 for the treatment of diabetic macular edema (DME). Market share is currently zero, as it is in clinical trials. Competitors include Regeneron (Eylea), Roche (Vabysmo), and other anti-VEGF therapies.
- OCU300: A single-entity topical formulation of brinzolamide for managing chronic blepharitis and dry eye. Market share is currently zero, as it is in clinical trials. Competitors include Bausch + Lomb, Novartis, and other companies offering eye drops and treatments for blepharitis and dry eye.
Market Dynamics
Industry Overview
The ophthalmic pharmaceuticals market is growing due to an aging population and increasing prevalence of eye diseases. Gene therapies and novel biologics are areas of high interest.
Positioning
Oculis Holding AG aims to differentiate itself through its pipeline of novel therapies and its focus on addressing unmet needs in the ophthalmic market.
Total Addressable Market (TAM)
The global ophthalmic market is expected to reach $45 billion by 2028. Oculis Holding AG is positioning itself to capture a portion of this TAM with its pipeline of innovative therapies, targeting areas with high unmet needs.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Focus on unmet needs
- Experienced management team
- Gene therapy platform
Weaknesses
- Dependence on clinical trial success
- Limited commercialization experience
- Relatively small size
- High cash burn rate
Opportunities
- Positive clinical trial results
- Strategic partnerships
- Expansion into new indications
- Acquisition by a larger company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger companies
- Patent expirations
Competitors and Market Share
Key Competitors
- REGN
- ROCHE.SW
- ALVR
Competitive Landscape
Oculis Holding AG competes with established pharmaceutical companies and other biotech companies developing ophthalmic treatments. Its competitive advantage lies in its novel therapeutic candidates and focus on unmet needs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as it is a newly public company through SPAC merger.
Future Projections: Future growth depends on the success of its clinical trials and potential regulatory approvals.
Recent Initiatives: Recent initiatives include advancing OCU400, OCU200 and OCU300 through clinical trials and exploring strategic partnerships.
Summary
Oculis Holding AG is a clinical-stage biopharmaceutical company focused on ophthalmology, offering potential upside through its novel pipeline. However, the company relies heavily on clinical trial outcomes, faces intense competition, and needs to manage its cash burn effectively. The warrants' value is directly linked to the success of Oculis Holding AG.
Similar Companies
ALVR
Allovir Inc
ALVR
Allovir Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oculis Holding AG Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-03 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website |
Full time employees 32 | Website | ||
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.